Ovid Therapeutics rises as epilepsy drug shows clean safety

Ovid Therapeutics

18/03/2026 10:15

** Shares of biotech firm Ovid Therapeutics OVID.O rise about 16% to $2.33 premarket

** Says experimental epilepsy drug OV329 showed a clean safety profile in an early-stage study

** Volunteers given a 7 mg dose reported no treatment-related side effects; other events were mild and short-lived - OVID

** Says no signs of eye problems, a known risk with older drugs in the same class

** Plans a mid-stage trial in focal onset seizures, a common form of epilepsy, in Q2

** Also plans studies in rare childhood seizure disorders, including tuberous sclerosis complex and infantile spasms

** Raises $60 mln in a private funding round to support the studies

** Shares gained ~75% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))